Connetics Hit With Shareholder Lawsuit Over Failed Drug

Law360, New York (September 21, 2006, 12:00 AM EDT) -- Connetics Corp., a pharmaceutical company specializing in dermatological products, has been hit with a securities class action over allegations that it concealed a finding on a new drug which eventually caused the Food and Drug Administration to reject it.

The suit alleges that after a six-month study on mice, Connetics concealed the discovery that 55% of the mice treated with Velac, a new acne medication, developed tumors.

The company also falsified financial reports by failing to properly reserve for rebates, so that it could cash in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.